

1. (original): A crystalline polymorph of  $(\pm)$ -7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoic acid monosodium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values ( $\text{\AA}$ ): 7.6 (vs), 6.10 (s), and 4.37 (s), wherein (vs) = very strong intensity and (s) = strong intensity.
2. (original): A crystalline polymorph of  $(\pm)$ -7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoic acid monosodium salt according to claim 1 which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values ( $\text{\AA}$ ): 10.1 (m), 7.6 (vs), 6.10 (s), 5.09(m), 4.37 (s) and 3.07(m), wherein (vs) = very strong intensity, (s) = strong intensity and (m) = medium intensity.
3. (original): A crystalline polymorph of  $(\pm)$ -7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoic acid monosodium salt according to claim 1 which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values ( $\text{\AA}$ ): 29.2 (w), 15.0 (vw), 10.1 (m), 7.6 (vs), 6.10 (s), 5.09(m), 4.37 (s), 3.83 (w) and 3.07(m), wherein (vs) = very strong intensity, (s) = strong intensity, (m) = medium intensity, (w) = weak intensity and (vw) = very weak intensity.
4. (currently amended): A process for the preparation of a crystalline polymorph according to ~~claims 1 to 3~~ claim 1, wherein Fluvastatin sodium is filtered off from an aqueous suspension.
5. (currently amended): A process according to claim 4 for in which the aqueous suspension is prepared from any of the known crystalline forms or the amorphous form of ~~Forms of~~ Fluvastatin sodium.
6. (original): A process according to claim 4 in which an aqueous suspension of Fluvastatin sodium is stirred before filtration.
7. (original): A pharmaceutical composition comprising an effective amount of a crystalline polymorphic form according to claim 1 and a pharmaceutically acceptable carrier.
8. (new): A process for the preparation of a crystalline polymorph according to claim 2, wherein Fluvastatin sodium is filtered off from an aqueous suspension.

9. (new): A process for the preparation of a crystalline polymorph according to claim 3, wherein Fluvastatin sodium is filtered off from an aqueous suspension.